The U.S. Food and Drug Administration approved Icotyde (icotrokinra), an oral IL‑23 receptor antagonist developed by Protagonist Therapeutics in partnership with Johnson & Johnson. Approval was based on the Iconic Phase III program that enrolled roughly 2,500 patients across four trials and included head‑to‑head comparators and site‑specific efficacy endpoints. J&J positions Icotyde as the first oral peptide in the IL‑23 class to compete with high‑selling injectable biologics; the company projects multibillion‑dollar peak sales. Clinical uptake and payer coverage will determine how the oral option affects the established injectable market for IL‑23 inhibitors.